secukinumab (Cosentyx) -

secukinumab (Cosentyx)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Musculo-skeletal disorders | Skin disorders
Summary
Secukinumab is accepted for restricted use within NHS Scotland as monotherapy or in combination with methotrexate, for active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.
UKMi comment
Use is restricted to patients whose disease has not responded to adequate trials of at least two standard DMARDs either individually or in combination
Related links: